Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $106.20

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus recommendation of “Hold” from the twenty-two analysts that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $106.20.

A number of research analysts have recently weighed in on the stock. Barclays dropped their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research note on Thursday, February 12th. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their target price for the company from $94.00 to $120.00 in a report on Monday, January 5th. BTIG Research reissued a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. lifted its stake in shares of Zimmer Biomet by 4,020.2% during the fourth quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock valued at $62,742,000 after buying an additional 680,818 shares during the period. Monetary Solutions Ltd acquired a new stake in Zimmer Biomet during the fourth quarter worth approximately $30,000. Virtu Financial LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $1,801,000. Dean Capital Management grew its stake in Zimmer Biomet by 11.2% in the 4th quarter. Dean Capital Management now owns 19,528 shares of the medical equipment provider’s stock worth $1,756,000 after acquiring an additional 1,960 shares during the period. Finally, Cambient Family Office LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $379,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $94.08 on Friday. The firm has a market capitalization of $18.41 billion, a PE ratio of 26.58, a P/E/G ratio of 1.92 and a beta of 0.58. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44. The firm’s 50-day simple moving average is $92.13 and its 200 day simple moving average is $95.60. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the firm posted $2.31 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts predict that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.